Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. CSII Peers
See (CSII) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CSII | $20.00 | +0.15% | 844M | -20.83 | -$0.96 | N/A |
| ABT | $136.01 | +0.00% | 237.1B | 17.72 | $7.69 | +1.67% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $107.41 | +0.00% | 155B | 76.46 | $1.37 | N/A |
| SYK | $395.63 | +0.00% | 151.6B | 53.68 | $7.39 | +0.84% |
| MDT | $87.17 | +0.00% | 113.7B | 24.58 | $3.61 | +3.18% |
| EW | $78.21 | +0.00% | 45.3B | 31.90 | $2.42 | N/A |
| DXCM | $87.29 | +0.00% | 32.8B | 62.84 | $1.33 | N/A |
| STE | $240.22 | +0.00% | 23.9B | 39.39 | $6.16 | +0.94% |
| PHG | $23.98 | +0.00% | 22.4B | 80.65 | $0.30 | +3.66% |
Stock Comparison
CSII vs ABT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ABT has a market cap of 237.1B. Regarding current trading prices, CSII is priced at $20.00, while ABT trades at $136.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ABT's P/E ratio is 17.72. In terms of profitability, CSII's ROE is -0.14%, compared to ABT's ROE of +0.31%. Regarding short-term risk, CSII is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BSX-PA Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CSII is priced at $20.00, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CSII's ROE is -0.14%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BSX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BSX has a market cap of 155B. Regarding current trading prices, CSII is priced at $20.00, while BSX trades at $107.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BSX's P/E ratio is 76.46. In terms of profitability, CSII's ROE is -0.14%, compared to BSX's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SYK Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SYK has a market cap of 151.6B. Regarding current trading prices, CSII is priced at $20.00, while SYK trades at $395.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SYK's P/E ratio is 53.68. In terms of profitability, CSII's ROE is -0.14%, compared to SYK's ROE of +0.11%. Regarding short-term risk, CSII is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs MDT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, MDT has a market cap of 113.7B. Regarding current trading prices, CSII is priced at $20.00, while MDT trades at $87.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas MDT's P/E ratio is 24.58. In terms of profitability, CSII's ROE is -0.14%, compared to MDT's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs EW Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, EW has a market cap of 45.3B. Regarding current trading prices, CSII is priced at $20.00, while EW trades at $78.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas EW's P/E ratio is 31.90. In terms of profitability, CSII's ROE is -0.14%, compared to EW's ROE of +0.49%. Regarding short-term risk, CSII is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs DXCM Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, DXCM has a market cap of 32.8B. Regarding current trading prices, CSII is priced at $20.00, while DXCM trades at $87.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas DXCM's P/E ratio is 62.84. In terms of profitability, CSII's ROE is -0.14%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, CSII is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs STE Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, STE has a market cap of 23.9B. Regarding current trading prices, CSII is priced at $20.00, while STE trades at $240.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas STE's P/E ratio is 39.39. In terms of profitability, CSII's ROE is -0.14%, compared to STE's ROE of +0.09%. Regarding short-term risk, CSII is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs PHG Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PHG has a market cap of 22.4B. Regarding current trading prices, CSII is priced at $20.00, while PHG trades at $23.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PHG's P/E ratio is 80.65. In terms of profitability, CSII's ROE is -0.14%, compared to PHG's ROE of +0.03%. Regarding short-term risk, CSII is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs PODD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PODD has a market cap of 21.1B. Regarding current trading prices, CSII is priced at $20.00, while PODD trades at $314.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PODD's P/E ratio is 54.05. In terms of profitability, CSII's ROE is -0.14%, compared to PODD's ROE of +0.35%. Regarding short-term risk, CSII is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ZBH Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ZBH has a market cap of 18.6B. Regarding current trading prices, CSII is priced at $20.00, while ZBH trades at $91.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ZBH's P/E ratio is 20.90. In terms of profitability, CSII's ROE is -0.14%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, CSII is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ABMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CSII is priced at $20.00, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CSII's ROE is -0.14%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ALGN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ALGN has a market cap of 14.1B. Regarding current trading prices, CSII is priced at $20.00, while ALGN trades at $189.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ALGN's P/E ratio is 35.26. In terms of profitability, CSII's ROE is -0.14%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, CSII is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SNN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SNN has a market cap of 13.4B. Regarding current trading prices, CSII is priced at $20.00, while SNN trades at $30.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SNN's P/E ratio is 32.56. In terms of profitability, CSII's ROE is -0.14%, compared to SNN's ROE of +0.08%. Regarding short-term risk, CSII is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SWAV Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CSII is priced at $20.00, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CSII's ROE is -0.14%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, CSII is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs PEN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PEN has a market cap of 9.7B. Regarding current trading prices, CSII is priced at $20.00, while PEN trades at $256.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PEN's P/E ratio is 232.44. In terms of profitability, CSII's ROE is -0.14%, compared to PEN's ROE of +0.04%. Regarding short-term risk, CSII is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs GMED Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, GMED has a market cap of 8.1B. Regarding current trading prices, CSII is priced at $20.00, while GMED trades at $59.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas GMED's P/E ratio is 44.90. In terms of profitability, CSII's ROE is -0.14%, compared to GMED's ROE of +0.05%. Regarding short-term risk, CSII is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BIO-B Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, CSII is priced at $20.00, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, CSII's ROE is -0.14%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, CSII is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs BIO Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BIO has a market cap of 6.7B. Regarding current trading prices, CSII is priced at $20.00, while BIO trades at $241.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BIO's P/E ratio is -3.24. In terms of profitability, CSII's ROE is -0.14%, compared to BIO's ROE of -0.32%. Regarding short-term risk, CSII is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BRKR Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BRKR has a market cap of 6.3B. Regarding current trading prices, CSII is priced at $20.00, while BRKR trades at $41.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BRKR's P/E ratio is 80.58. In terms of profitability, CSII's ROE is -0.14%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, CSII is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs GKOS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, CSII is priced at $20.00, while GKOS trades at $103.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas GKOS's P/E ratio is -45.20. In terms of profitability, CSII's ROE is -0.14%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, CSII is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs NARI Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CSII is priced at $20.00, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas NARI's P/E ratio is -59.24. In terms of profitability, CSII's ROE is -0.14%, compared to NARI's ROE of -0.18%. Regarding short-term risk, CSII is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs IRTC Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, IRTC has a market cap of 4.7B. Regarding current trading prices, CSII is priced at $20.00, while IRTC trades at $153.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas IRTC's P/E ratio is -46.78. In terms of profitability, CSII's ROE is -0.14%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, CSII is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs TMDX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, CSII is priced at $20.00, while TMDX trades at $134.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas TMDX's P/E ratio is 91.62. In terms of profitability, CSII's ROE is -0.14%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, CSII is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ITGR Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, CSII is priced at $20.00, while ITGR trades at $122.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ITGR's P/E ratio is 56.70. In terms of profitability, CSII's ROE is -0.14%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, CSII is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs INSP Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, INSP has a market cap of 3.9B. Regarding current trading prices, CSII is priced at $20.00, while INSP trades at $129.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas INSP's P/E ratio is 59.76. In terms of profitability, CSII's ROE is -0.14%, compared to INSP's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs AXNX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CSII is priced at $20.00, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CSII's ROE is -0.14%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CSII is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs PRCT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PRCT has a market cap of 3.1B. Regarding current trading prices, CSII is priced at $20.00, while PRCT trades at $57.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PRCT's P/E ratio is -33.47. In terms of profitability, CSII's ROE is -0.14%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, CSII is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs LIVN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, CSII is priced at $20.00, while LIVN trades at $45.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas LIVN's P/E ratio is -11.24. In terms of profitability, CSII's ROE is -0.14%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, CSII is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs NUVA Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CSII is priced at $20.00, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CSII's ROE is -0.14%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CSII is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs UFPT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, CSII is priced at $20.00, while UFPT trades at $244.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas UFPT's P/E ratio is 30.96. In terms of profitability, CSII's ROE is -0.14%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, CSII is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CNMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, CSII is priced at $20.00, while CNMD trades at $52.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CNMD's P/E ratio is 14.19. In terms of profitability, CSII's ROE is -0.14%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, CSII is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ATEC Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, CSII is priced at $20.00, while ATEC trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ATEC's P/E ratio is -9.59. In terms of profitability, CSII's ROE is -0.14%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, CSII is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs AORT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00, while AORT trades at $31.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AORT's P/E ratio is -60.26. In terms of profitability, CSII's ROE is -0.14%, compared to AORT's ROE of -0.07%. Regarding short-term risk, CSII is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs HSKA Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CSII's ROE is -0.14%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CSII is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs AHCO Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00, while AHCO trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AHCO's P/E ratio is 16.21. In terms of profitability, CSII's ROE is -0.14%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, CSII is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ESTA Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00, while ESTA trades at $42.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ESTA's P/E ratio is -13.91. In terms of profitability, CSII's ROE is -0.14%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, CSII is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs TNDM Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00, while TNDM trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas TNDM's P/E ratio is -6.18. In terms of profitability, CSII's ROE is -0.14%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, CSII is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SILK Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SILK's P/E ratio is -18.96. In terms of profitability, CSII's ROE is -0.14%, compared to SILK's ROE of -0.29%. Regarding short-term risk, CSII is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for CSII.
CSII vs FNA Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas FNA's P/E ratio is -19.83. In terms of profitability, CSII's ROE is -0.14%, compared to FNA's ROE of -0.36%. Regarding short-term risk, CSII is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SSII Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00, while SSII trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SSII's P/E ratio is -70.75. In terms of profitability, CSII's ROE is -0.14%, compared to SSII's ROE of -1.33%. Regarding short-term risk, CSII is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs INMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, INMD has a market cap of 1B. Regarding current trading prices, CSII is priced at $20.00, while INMD trades at $14.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas INMD's P/E ratio is 6.65. In terms of profitability, CSII's ROE is -0.14%, compared to INMD's ROE of +0.25%. Regarding short-term risk, CSII is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs IART Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, IART has a market cap of 1B. Regarding current trading prices, CSII is priced at $20.00, while IART trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas IART's P/E ratio is -34.87. In terms of profitability, CSII's ROE is -0.14%, compared to IART's ROE of -0.03%. Regarding short-term risk, CSII is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SIBN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SIBN has a market cap of 780.3M. Regarding current trading prices, CSII is priced at $20.00, while SIBN trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SIBN's P/E ratio is -29.06. In terms of profitability, CSII's ROE is -0.14%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, CSII is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs IRMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, IRMD has a market cap of 769.4M. Regarding current trading prices, CSII is priced at $20.00, while IRMD trades at $59.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas IRMD's P/E ratio is 39.04. In terms of profitability, CSII's ROE is -0.14%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, CSII is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CRY Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, CSII is priced at $20.00, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CRY's P/E ratio is 425.71. In terms of profitability, CSII's ROE is -0.14%, compared to CRY's ROE of -0.07%. Regarding short-term risk, CSII is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CBLL Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CBLL has a market cap of 671.2M. Regarding current trading prices, CSII is priced at $20.00, while CBLL trades at $18.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CBLL's P/E ratio is -14.86. In terms of profitability, CSII's ROE is -0.14%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, CSII is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BFLY-WT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BFLY-WT has a market cap of 584.9M. Regarding current trading prices, CSII is priced at $20.00, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, CSII's ROE is -0.14%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, CSII is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs APEN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CSII is priced at $20.00, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas APEN's P/E ratio is -9.43. In terms of profitability, CSII's ROE is -0.14%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CSII is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs AVNS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AVNS has a market cap of 577.6M. Regarding current trading prices, CSII is priced at $20.00, while AVNS trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AVNS's P/E ratio is -1.51. In terms of profitability, CSII's ROE is -0.14%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, CSII is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs KIDS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, KIDS has a market cap of 541.5M. Regarding current trading prices, CSII is priced at $20.00, while KIDS trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas KIDS's P/E ratio is -12.42. In terms of profitability, CSII's ROE is -0.14%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, CSII is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs RXST Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, RXST has a market cap of 533.2M. Regarding current trading prices, CSII is priced at $20.00, while RXST trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas RXST's P/E ratio is -19.88. In terms of profitability, CSII's ROE is -0.14%, compared to RXST's ROE of -0.10%. Regarding short-term risk, CSII is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs AXGN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AXGN has a market cap of 499.2M. Regarding current trading prices, CSII is priced at $20.00, while AXGN trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AXGN's P/E ratio is -68.50. In terms of profitability, CSII's ROE is -0.14%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, CSII is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BFLY Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BFLY has a market cap of 478.5M. Regarding current trading prices, CSII is priced at $20.00, while BFLY trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BFLY's P/E ratio is -6.45. In terms of profitability, CSII's ROE is -0.14%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, CSII is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BVS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BVS has a market cap of 462.5M. Regarding current trading prices, CSII is priced at $20.00, while BVS trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BVS's P/E ratio is -14.52. In terms of profitability, CSII's ROE is -0.14%, compared to BVS's ROE of -0.21%. Regarding short-term risk, CSII is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CTKB Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CTKB has a market cap of 440.8M. Regarding current trading prices, CSII is priced at $20.00, while CTKB trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CTKB's P/E ratio is -38.67. In terms of profitability, CSII's ROE is -0.14%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, CSII is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs OFIX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, OFIX has a market cap of 438M. Regarding current trading prices, CSII is priced at $20.00, while OFIX trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas OFIX's P/E ratio is -3.02. In terms of profitability, CSII's ROE is -0.14%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, CSII is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SRDX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SRDX has a market cap of 418.7M. Regarding current trading prices, CSII is priced at $20.00, while SRDX trades at $29.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SRDX's P/E ratio is -20.91. In terms of profitability, CSII's ROE is -0.14%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, CSII is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SMLR Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SMLR has a market cap of 395M. Regarding current trading prices, CSII is priced at $20.00, while SMLR trades at $38.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SMLR's P/E ratio is -14.82. In terms of profitability, CSII's ROE is -0.14%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, CSII is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs PACB Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PACB has a market cap of 387.1M. Regarding current trading prices, CSII is priced at $20.00, while PACB trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PACB's P/E ratio is -0.47. In terms of profitability, CSII's ROE is -0.14%, compared to PACB's ROE of -1.70%. Regarding short-term risk, CSII is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs TMCI Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, TMCI has a market cap of 378.7M. Regarding current trading prices, CSII is priced at $20.00, while TMCI trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas TMCI's P/E ratio is -7.08. In terms of profitability, CSII's ROE is -0.14%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, CSII is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs OM Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, OM has a market cap of 367.4M. Regarding current trading prices, CSII is priced at $20.00, while OM trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas OM's P/E ratio is -0.72. In terms of profitability, CSII's ROE is -0.14%, compared to OM's ROE of -1.45%. Regarding short-term risk, CSII is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SENS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SENS has a market cap of 361.5M. Regarding current trading prices, CSII is priced at $20.00, while SENS trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SENS's P/E ratio is -4.36. In terms of profitability, CSII's ROE is -0.14%, compared to SENS's ROE of -7.46%. Regarding short-term risk, CSII is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs VREX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, VREX has a market cap of 355.7M. Regarding current trading prices, CSII is priced at $20.00, while VREX trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas VREX's P/E ratio is -8.32. In terms of profitability, CSII's ROE is -0.14%, compared to VREX's ROE of -0.08%. Regarding short-term risk, CSII is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs NPCE Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, NPCE has a market cap of 343.7M. Regarding current trading prices, CSII is priced at $20.00, while NPCE trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas NPCE's P/E ratio is -12.78. In terms of profitability, CSII's ROE is -0.14%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, CSII is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs NNOX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, NNOX has a market cap of 326.1M. Regarding current trading prices, CSII is priced at $20.00, while NNOX trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas NNOX's P/E ratio is -5.62. In terms of profitability, CSII's ROE is -0.14%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, CSII is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CLPT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CLPT has a market cap of 318.3M. Regarding current trading prices, CSII is priced at $20.00, while CLPT trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CLPT's P/E ratio is -14.82. In terms of profitability, CSII's ROE is -0.14%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, CSII is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CERS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CERS has a market cap of 282.9M. Regarding current trading prices, CSII is priced at $20.00, while CERS trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CERS's P/E ratio is -14.80. In terms of profitability, CSII's ROE is -0.14%, compared to CERS's ROE of -0.35%. Regarding short-term risk, CSII is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs VMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, VMD has a market cap of 276.7M. Regarding current trading prices, CSII is priced at $20.00, while VMD trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas VMD's P/E ratio is 23.33. In terms of profitability, CSII's ROE is -0.14%, compared to VMD's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SNWV Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SNWV has a market cap of 275.7M. Regarding current trading prices, CSII is priced at $20.00, while SNWV trades at $32.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SNWV's P/E ratio is -5.17. In terms of profitability, CSII's ROE is -0.14%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, CSII is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ZIMV Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ZIMV has a market cap of 274.7M. Regarding current trading prices, CSII is priced at $20.00, while ZIMV trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ZIMV's P/E ratio is -10.93. In terms of profitability, CSII's ROE is -0.14%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, CSII is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs PTHL Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PTHL has a market cap of 261.2M. Regarding current trading prices, CSII is priced at $20.00, while PTHL trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PTHL's P/E ratio is -366.60. In terms of profitability, CSII's ROE is -0.14%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, CSII is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs QTRX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, QTRX has a market cap of 259.9M. Regarding current trading prices, CSII is priced at $20.00, while QTRX trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas QTRX's P/E ratio is -5.40. In terms of profitability, CSII's ROE is -0.14%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, CSII is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BWAY Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BWAY has a market cap of 245.2M. Regarding current trading prices, CSII is priced at $20.00, while BWAY trades at $13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BWAY's P/E ratio is 58.98. In terms of profitability, CSII's ROE is -0.14%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, CSII is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CATX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CATX has a market cap of 242.7M. Regarding current trading prices, CSII is priced at $20.00, while CATX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CATX's P/E ratio is -2.66. In terms of profitability, CSII's ROE is -0.14%, compared to CATX's ROE of -0.27%. Regarding short-term risk, CSII is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs TCMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, TCMD has a market cap of 237.8M. Regarding current trading prices, CSII is priced at $20.00, while TCMD trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas TCMD's P/E ratio is 15.50. In terms of profitability, CSII's ROE is -0.14%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, CSII is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs MASS Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, MASS has a market cap of 232.4M. Regarding current trading prices, CSII is priced at $20.00, while MASS trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas MASS's P/E ratio is -2.92. In terms of profitability, CSII's ROE is -0.14%, compared to MASS's ROE of -0.13%. Regarding short-term risk, CSII is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs MXCT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, MXCT has a market cap of 230.7M. Regarding current trading prices, CSII is priced at $20.00, while MXCT trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas MXCT's P/E ratio is -5.42. In terms of profitability, CSII's ROE is -0.14%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, CSII is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BSGM Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BSGM has a market cap of 227.1M. Regarding current trading prices, CSII is priced at $20.00, while BSGM trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BSGM's P/E ratio is -15.70. In terms of profitability, CSII's ROE is -0.14%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, CSII is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs NVRO Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CSII is priced at $20.00, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CSII's ROE is -0.14%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CSII is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs SGHT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, SGHT has a market cap of 210.4M. Regarding current trading prices, CSII is priced at $20.00, while SGHT trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas SGHT's P/E ratio is -4.15. In terms of profitability, CSII's ROE is -0.14%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, CSII is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs EYES Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, CSII is priced at $20.00, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas EYES's P/E ratio is N/A. In terms of profitability, CSII's ROE is -0.14%, compared to EYES's ROE of -0.26%. Regarding short-term risk, CSII is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs TLSI Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, TLSI has a market cap of 195.6M. Regarding current trading prices, CSII is priced at $20.00, while TLSI trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas TLSI's P/E ratio is -4.68. In terms of profitability, CSII's ROE is -0.14%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, CSII is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs INGN Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, INGN has a market cap of 190.9M. Regarding current trading prices, CSII is priced at $20.00, while INGN trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas INGN's P/E ratio is -6.17. In terms of profitability, CSII's ROE is -0.14%, compared to INGN's ROE of -0.15%. Regarding short-term risk, CSII is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs PROF Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, PROF has a market cap of 183.4M. Regarding current trading prices, CSII is priced at $20.00, while PROF trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas PROF's P/E ratio is -5.04. In terms of profitability, CSII's ROE is -0.14%, compared to PROF's ROE of -0.70%. Regarding short-term risk, CSII is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ELMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ELMD has a market cap of 181.5M. Regarding current trading prices, CSII is priced at $20.00, while ELMD trades at $21.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ELMD's P/E ratio is 27.39. In terms of profitability, CSII's ROE is -0.14%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, CSII is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs CVRX Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, CVRX has a market cap of 157.5M. Regarding current trading prices, CSII is priced at $20.00, while CVRX trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas CVRX's P/E ratio is -2.82. In terms of profitability, CSII's ROE is -0.14%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, CSII is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs RPID Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, RPID has a market cap of 153M. Regarding current trading prices, CSII is priced at $20.00, while RPID trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas RPID's P/E ratio is -3.39. In terms of profitability, CSII's ROE is -0.14%, compared to RPID's ROE of -0.56%. Regarding short-term risk, CSII is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs LNSR Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, LNSR has a market cap of 152.3M. Regarding current trading prices, CSII is priced at $20.00, while LNSR trades at $13.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas LNSR's P/E ratio is -2.63. In terms of profitability, CSII's ROE is -0.14%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, CSII is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ANIK Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ANIK has a market cap of 151M. Regarding current trading prices, CSII is priced at $20.00, while ANIK trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ANIK's P/E ratio is -14.04. In terms of profitability, CSII's ROE is -0.14%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, CSII is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs RCEL Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, RCEL has a market cap of 139.3M. Regarding current trading prices, CSII is priced at $20.00, while RCEL trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas RCEL's P/E ratio is -2.41. In terms of profitability, CSII's ROE is -0.14%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, CSII is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs AVR Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, AVR has a market cap of 138.7M. Regarding current trading prices, CSII is priced at $20.00, while AVR trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas AVR's P/E ratio is -1.07. In terms of profitability, CSII's ROE is -0.14%, compared to AVR's ROE of -2.92%. Regarding short-term risk, CSII is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs OWLT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, OWLT has a market cap of 138.5M. Regarding current trading prices, CSII is priced at $20.00, while OWLT trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas OWLT's P/E ratio is -5.20. In terms of profitability, CSII's ROE is -0.14%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, CSII is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs BDMD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, BDMD has a market cap of 137.9M. Regarding current trading prices, CSII is priced at $20.00, while BDMD trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas BDMD's P/E ratio is 7.88. In terms of profitability, CSII's ROE is -0.14%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, CSII is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs LUCD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, LUCD has a market cap of 119M. Regarding current trading prices, CSII is priced at $20.00, while LUCD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas LUCD's P/E ratio is -0.94. In terms of profitability, CSII's ROE is -0.14%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, CSII is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs LUNG Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, LUNG has a market cap of 108.3M. Regarding current trading prices, CSII is priced at $20.00, while LUNG trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas LUNG's P/E ratio is -1.87. In terms of profitability, CSII's ROE is -0.14%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, CSII is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs ICAD Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, ICAD has a market cap of 102.2M. Regarding current trading prices, CSII is priced at $20.00, while ICAD trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas ICAD's P/E ratio is -19.58. In terms of profitability, CSII's ROE is -0.14%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, CSII is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs MGRM Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, MGRM has a market cap of 102.1M. Regarding current trading prices, CSII is priced at $20.00, while MGRM trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas MGRM's P/E ratio is -5.72. In terms of profitability, CSII's ROE is -0.14%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, CSII is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.
CSII vs XTNT Comparison
CSII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSII stands at 844M. In comparison, XTNT has a market cap of 99.6M. Regarding current trading prices, CSII is priced at $20.00, while XTNT trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSII currently has a P/E ratio of -20.83, whereas XTNT's P/E ratio is -7.95. In terms of profitability, CSII's ROE is -0.14%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, CSII is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for CSII.